Keep checking for updates and new content.

Brachytherapy

Single-fraction, high-dose brachytherapy may be viable for localized prostate cancer

July 2, 2017

Single-fraction 19 Gy high dose–rate brachytherapy may be a safe and effective treatment alternative for men with localized prostate cancer, according to study results. Read the article here.

Read the article or watch the video →

Updated Guideline on Brachytherapy in Prostate Cancer

May 7, 2017

The Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer was updated to account for new evidence. Read the article here.

Read the article or watch the video →

Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers

February 19, 2017

Brachytherapy, a form of localized radiation therapy, has been shown to be one of the most effective methods for delivering high radiation doses to the cancer; however, recent evidence suggests that increasing the localized radiation dose without bound may cause unacceptable increases in long-term side effects. This review focuses on methods that have been proposed, […]

Read the article or watch the video →

Woman to Watch: Dr. Juanita Crook

January 2, 2017

Dr. Juanita Crook, formerly with Princess Margaret Hospital, is now a professor of radiation oncology at UBC and an oncologist with the B.C. Cancer Agency. She specializes in brachytherapy. Read the article here.

Read the article or watch the video →

Dr Crook webinar on brachytherapy

October 21, 2016

Really excellent and well presented facts and documentation About 50 minutes (including a bit painful 5 minutes to start up)but well worth listening to When you link to the site it will ask for your name and email address before opening View the Webinar.

Read the article or watch the video →

Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy

July 24, 2016

A study evaluated experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, the side-effect profile after the second brachytherapy […]

Read the article or watch the video →

New advances in salvage brachytherapy

May 23, 2016

Calgary Tom Baker Cancer Centre radiation oncologist Dr. Siraj Husain discusses advances and new studies in the growing area of Salvage Brachytherapy. He starts with a quick but informative overview of prostate cancer, its diagnosis and treatments, and then launches into studies with graphic slides that show the groundbreaking work that is being done today […]

Read the article or watch the video →

Advances in Radiation Treatment for Prostate Cancer

February 7, 2016

This somewhat general article discusses various radiation options for prostate cancer, including: High Dose Rate brachytherapy – a form of focal therapy High fraction external beam radiotherapy Read the article.

Read the article or watch the video →

High-dose-rate brachytherapy (HDRBT) monotherapy — 10 year results

November 1, 2015

High-dose-rate (HDR) brachytherapy was originally used with external beam radiation therapy (EBRT) to increase the dose to the prostate without injuring the bladder or rectum. Numerous studies have reported HDR brachytherapy is safe and effective. It has been adapted for use without EBRT for cases not requiring lymph node treatment. Read the article.

Read the article or watch the video →

High-dose-rate brachytherapy boost for prostate cancer: rationale and technique

January 6, 2015

High-dose-rate brachytherapy (HDR) is a method of conformal dose escalation to the prostate. It can be used as a local boost in combination with external beam radiotherapy, with a high degree of efficacy and low rate of long term toxicity. Data consistently reports relapse free survival rates of greater than 90% for intermediate risk patients […]

Read the article or watch the video →